SCM
AKBA icon

Sterling Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Sterling Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55K Sell
1,362
-6,270
-82% -$7.46K ﹤0.01% 3050
2026
Q1 		$10.6K Sell
7,632
-5,525
-42% -$7.59K ﹤0.01% 2340
2025
Q4 		$21.2K Sell
13,157
-2,248
-15% -$4.71K ﹤0.01% 2197
2025
Q3 		$42.1K Buy
15,405
+9,356
+155% +$31.1K ﹤0.01% 1815
2025
Q2 		$22K Buy
6,049
+2,639
+77% +$7.25K ﹤0.01% 1761
2025
Q1 		$6.55K Sell
3,410
-2,654
-44% -$5.42K ﹤0.01% 2026
2024
Q4 		$11.5K Buy
6,064
+5,445
+880% +$9.46K ﹤0.01% 2102
2024
Q3 		$817 Buy
+619
New +$827 ﹤0.01% 2644
2018
Q2 		– Sell
-32,425
Closed -$309K – 840
2018
Q1 		$309K Buy
+32,425
New +$454K ﹤0.01% 795
2017
Q4 		– Sell
-42,903
Closed -$844K – 876
2017
Q3 		$844K Buy
+42,903
New +$660K 0.01% 677

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sterling Capital Management's AKBA Position: Q2 2026 in Review

Sterling Capital Management reduced its Akebia Therapeutics (AKBA) stake by 82% in Q2 2026, selling an estimated $7.46K and leaving 1,362 shares worth $1.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3050.

Sterling Capital Management first reported a position in AKBA in Q3 2017 and has held it in 10 quarters since. The position peaked at $844K in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Sterling Capital Management held 1,362 shares of Akebia Therapeutics worth $1.55K as of Q2 2026.
  • Sterling Capital Management sold 6,270 Akebia Therapeutics shares in Q2 2026, an estimated $7.46K.
  • Akebia Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3050 holding.
  • Sterling Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 10 quarters since.
  • Sterling Capital Management's Akebia Therapeutics position peaked at $844K in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.